Institut Pasteur

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Université Paris Diderot-Paris 7

Université Paris—sud

UniversitÉ Paris Descartes

Institut Gustave Roussy

Université Pierre Et Marie Curie

Assistance Publique - Hopitaux De Paris (aphp)

Institute Pasteur

Centre Hospitalier De Versailles

Instituto Nazionale Per Le Malattie Infettie Irccs Lazzaro Spallanzani

Université Paris-Saclay

Inserm

Istituto Nazionale Per Le Malattie Infettive "la Spallanzani" I.r.c.c.s

Marie-Lise Gougeon

Hela Saidi

Beatrice Poirier-Beaudoin

Valerie Seffer

Marie-Therese Melki

Maria-Thérèse Melki

Nicolas Fazilleau

Nicole Prada

Manuelle Viguier

Hervé Bachelez

Guido Kroemer

Michel Robert Popoff

Jean-Luc Perfettini

Awatef Allouch

Mauro Piacentini

Béatrice Poirier-Beaudoin

Anne Collignon

Valérie Seffer

Alban Le Monnier

Héla Saidi

Béatrice Poirier-Beaudouin

The quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample, in particular human serum and/or Cerebrospinal Fluid (CSF) is detailed. An in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved and an in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved are detailed. A kit to quantitate the specific antibodies for at least one redox form of HMGB1, in particular human HMGB1 is detailed.

Assay to detect and quantitate specific antibodies for various redox forms of HMGB1

Quantitation of specific antibodies for at least one redox form of High mobility group box 1 (HMGB1) contained in a biological sample. An in vitro method for assessing the state of progression of a disease or a disorder in which HMGB1 is involved. An in vitro method for the identification of predisposition, prognostic or diagnostic biomarkers of a disease or a disorder in which HMGB1 is involved. A kit to quantitate said specific antibodies for at least one redox form of HMGB1.

Assay to detect and quantitate specific an antibodies for various redox forms of HMGB1

The present invention relates to the field ofinfections. Methods of diagnosing, treating and preventing-associated disease and recurrent CDAD are disclosed herein.

Predictive value of-specific immune response for recurrence and disease outcome

A massive clonal expansion of activated CD8T-cells with increased frequency of HPV 16-specific CD8T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.

Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus

Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.

Method for quantitating total HMGB1 protein in biological samples

The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.

Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections

The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders

Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence

Growing community of inventors

Clamart, France

Marie-Lise Gougeon